CD73 Inhibitor Screening Assay Kit

Catalog #
72055
$935 *
Size: 96 reactions
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The CD73 Inhibitor Screening Assay Kit is a 96-well colorimetric assay designed to measure the activity of CD73 for screening and profiling applications. 

This product has been cited 2 times.

Synonyms
5'- nucleotidase, Ecto-5'-nucleotidase, activity assay kit, colorimetric assay
Product Info
Storage and Usage
Citations2
Assay Kit Format
Colorimetric
Supplied As
The kit contains enough purified CD73 enzyme (BPS Bioscience #71184), AMP, CD73 assay buffer and colorimetric detection reagent for 100 enzyme reactions.  
Materials Required But Not Supplied
  • UV/Vis spectrophotometer microplate reader capable of reading λ=630 nm 
  • Adjustable micropipettor and sterile tips 
Format
Catalog # Name Amount Storage
71184 CD73, His-Tag* 5 µg -80°C Avoid
freeze/
thaw
cycles! 
74000 5x CD73 Assay Buffer 2 x 1 ml -20°C
79496 500 µM AMP 1 ml -20°C
74001 Colorimetric Detection Reagent** 10 ml 4°C
79963 Transparent 96-well plate 1 Room Temp  

 

 

 

 

 

 

 

 

 


*The concentration of protein is lot-specific and will be indicated on the tube containing the protein.

**Colorimetric Detection Reagent is used to measure the free phosphate generated in the reaction catalyzed by CD73. Any other source of inorganic phosphate can interfere with the assay.

UniProt #
P21589
Background

Cluster of Differentiation 73 (CD73), also known as ecto-5’-nucleotidase (NT5E) degrades AMP into adenosine.  Adenosine is an anti-inflammatory molecule, and its regulation is crucial for immune system homeostasis. CD73 is expressed in several cell types, such as Treg cells and myeloid-derived suppressor cells. Upregulation of CD73 is linked to numerous cancer types, such as leukemia, glioblastoma, melanoma and ovarian and breast cancer. It is also linked to systemic lupus erythematosus. Its role in cancer makes CD73 inhibitors and antibodies promising therapeutical avenues for cancer and inflammatory diseases.

CD73/CD39 Immunotherapy

References

Antonioli, L., et al., Trends in Cancer, Vol. 2, No. 2, 95-109.